TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: ocular hemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in P+M volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Abdominal circumference reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perfusion Index (PI) in temporal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User satisfaction with audio processor
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: SAPS hallucination subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fall in haematocrit ≥5 units following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to complete follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cost of completing follow-up
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Completion rate of follow-up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of top-quality embryos per woman
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: indicators of distress and well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Amprenavir intrinsic clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: onset time of muscle relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to 25% recovery of baseline first twitch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-cog11 cognitive assessment improvements
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: DSST cognitive assessment improvements
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dose-dependent effects on lipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy and safety of alirocumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: standing balance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean viral load changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence greater than 95%
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BFS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FACIT-Sp scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: reductions in drinks per drinking day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection rate (titre ≥ 1 : 40)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of stimuli pairs correctly discriminated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No vomiting in acute-emesis phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: No vomiting in delayed-emesis phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median nausea score in delayed-emesis phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Concentration of desflurane necessary to blunt changes in spectral entropy (EC50)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuous metabolic syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: maximum glucose infusion rate (GIR(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: area under curve for GIR during the first 3 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: poor outcome at day 90
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Need for allogenic RBC transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum urea nitrogen concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of infections per 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: candidal colonization per 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MWH use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: reduction in the number of infants reporting AOM episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced vaccine-type pneumococcal carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cultivable bacteria reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC NRS-R scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Care provider's satisfaction with analgesia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: loss of midperipheral visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period of oxygen dependency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Full enteral feeding achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Erythematous skin rashes
Endpoint domain: Adverse events/effects
Primary endpoint: Infections at the operative site
Endpoint domain: Adverse events/effects
Primary endpoint: Pelvic hematoma
Endpoint domain: Adverse events/effects
Primary endpoint: endometrial carcinoma incidence
Endpoint domain: Adverse events/effects
Primary endpoint: vaginitis incidence
Endpoint domain: Adverse events/effects
Primary endpoint: endometrial thickness change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Continuous abstinence time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Word List immediate and delayed recall
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Digit Span backwards test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of subjects with at least one adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of adenomas per subject
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Caecal intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Eligibility for treatment based on fracture risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for ephedrine injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in the number of AK lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: self-ratings of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Rates of major malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean timing of the first stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Need for operative treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: days to normal oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative stay-in-ward duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycogen synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lactate response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PI 3-kinase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BDI‐II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: K6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEER score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in scalp psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of angular stomatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Hemoglobin (Hb)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Serum Ferritin (SF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Days on antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient recruitment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Food and nutrient content of children's packed lunches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Voice function assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quadriceps strength recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cortisol responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: negative emotion ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knee joint dynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-axis systolic myocardial velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early diastolic myocardial velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: self reported infection related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of patients who were emesis-free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: earthquake-caused mortality
Endpoint domain: Mortality/survival
Primary endpoint: mean arterial pressure during isometric handgrip exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: postoperative abdominal pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: needle depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvements in arm function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of terminal hair growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diminished number of terminal hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of skin hyperpigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cardiovascular disease (CVD) events
Endpoint domain: Mortality/survival
Primary endpoint: Dose to medium vs. dose to water
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adherence to the split test procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high sensitive cardiac troponin I (hscTnI) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of myocardial infarction (MI 4a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects losing >10% of initial body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean time to progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OHIP scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DNA methylation plasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of treatment in melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful expulsion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: time of expulsion of urinary calculi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Postoperative nausea and/or vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower mean LAZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased risk of stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower mean WAZ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Framingham coronary heart disease risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Daily analgesic doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: mean delays in finger relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatology following treatment for bulimia nervosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean PEFR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in perceived barriers to exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Exercise level upon completion of the programme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence rate to negotiated exercise plans
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: explosive strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain sensation
Endpoint domain: Adverse events/effects
Primary endpoint: Probability of Target Attainment (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Failure Rate (CFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to Pay (WTP) for OTC scenario
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sleep disturbances due to pain
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Triage performance ability (KTAS level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of under-triage in KTAS
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Acute Respiratory Infections (ARI)
Endpoint domain: Adverse events/effects
Primary endpoint: Reach target SBP range within 30 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitological cure rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absence of any recurrence of atrial arrhythmia lasting >30 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: dyslipidaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean SIA (Surgical Induced Astigmatism)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieve a hemoglobin greater than 12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Achieve hemoglobin rise 3 g/dL or greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Attain higher serum transferrin saturation and ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sighting time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of targets missed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from center of mass of the target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mSASSS changes ≥ 2 at Week 104
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAMA and SAS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incidence of recurrent disease
Endpoint domain: Adverse events/effects
Primary endpoint: Improper MDI use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PFM underuse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the forward digit span task measuring short-term memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Median ICU length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Overall composite satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity to identify cardiac RLSs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mirtazapine vs placebo in psychological subgroup
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of OLV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subgingival microbial profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression of Joint Space Narrowing (JSN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days without use of loop diuretics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consecutive days of nondosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to conversion of AF to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion success within 90 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative healing complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Need for repeat orthopaedic surgery
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean IOP at 8 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Complete success with IOP ≤ 21 mmHg at 8 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: StimQ score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: lessening of symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain alleviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increased patient satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of anorgasmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal dryness improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dyspareunia improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pain change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite functional change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe somnolence
Endpoint domain: Adverse events/effects
Primary endpoint: Effective dose of dexmedetomidine for prevention of EA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social support dimension of quality of life
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: iPTH reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Calcium (Ca) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Phosphorus (P) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prescription for an oral beta-blocker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-reported prescription filling rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: necrotizing enterocolitis cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of cesarean delivery
Endpoint domain: Adverse events/effects
Primary endpoint: Self-efficacy for setting patient-centered goals
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean number of gout flares per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reporting ≥1 gout flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study completion rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status